Sentinel Pension Advisors’s Spero Therapeutics SPRO Stock Holding History

Sentinel Pension Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,000	Closed	-$20.8K	–	92
2022 Q4	$20.8K	Hold	12,000	–	–	0.01%	85
2022 Q3	$24K	Sell	12,000 -30,000	-71%	-$29.8K	0.01%	83
2022 Q2	$31K	Hold	42,000	–	–	0.01%	88
2022 Q1	$365K	Buy	42,000 +11,800	+39%	+$121K	0.12%	68
2021 Q4	$484K	Buy	30,200 +10,000	+50%	+$159K	0.15%	63
2021 Q3	$372K	Buy	+20,200	New	+$324K	0.13%	67
2021 Q2	–	Sell	-26,410	Closed	-$425K	–	98
2021 Q1	$425K	Buy	26,410 +2,795	+12%	+$49.2K	0.16%	54
2020 Q4	$458K	Buy	+23,615	New	+$368K	0.17%	57

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sentinel Pension Advisors's SPRO Position: Q1 2023 in Review

Sentinel Pension Advisors sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 12,000 shares — an estimated $20.8K sold.

Sentinel Pension Advisors first reported a position in SPRO in Q4 2020 and held it in 8 quarters. The position peaked at $484K in Q4 2021. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

Sentinel Pension Advisors reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
Sentinel Pension Advisors sold 12,000 Spero Therapeutics shares in Q1 2023, an estimated $20.8K.
Sentinel Pension Advisors first reported a position in Spero Therapeutics in Q4 2020 and held it in 8 quarters.
Sentinel Pension Advisors's Spero Therapeutics position peaked at $484K in Q4 2021.
48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Sentinel Pension Advisors's 13F filing for Q1 2023, filed 28 Apr 2023.